CYLC2

Summary

CYLC2 (cylicin 2, HGNC:2583) is a protein-coding gene on chromosome 9q31.1, encoding Cylicin-2 (Q14093). Plays a role in the establishment of normal sperm morphology during spermatogenesis.

Cylicin II (CYCL2) is specifically expressed in testis and is part of the cytoskeletal calyx of mammalian sperm heads. Cylicin II may play a role in the morphogenesis of the sperm head.

Source: NCBI Gene 1539 — RefSeq curated summary.

At a glance

• Gene–disease (curated): autism spectrum disorder (Limited, GenCC)
• GWAS associations: 5
• Clinical variants (ClinVar): 80 total
• MANE Select transcript: NM_001340

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2583
Approved symbol	CYLC2
Name	cylicin 2
Location	9q31.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000155833
Ensembl biotype	protein_coding
OMIM	604035
Entrez	1539

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 3 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000374798, ENST00000487798, ENST00000590560, ENST00000612124

RefSeq mRNA: 1 — MANE Select: NM_001340 NM_001340

CCDS: CCDS35085

Canonical transcript exons

ENST00000374798 — 8 exons

Exon	Start	End
ENSE00001464688	103018325	103018488
ENSE00001464689	103016888	103016961
ENSE00001520319	103011982	103012097
ENSE00001657203	103004969	103006378
ENSE00001717857	103001578	103001618
ENSE00001751362	103003142	103003263
ENSE00001757460	103004695	103004851
ENSE00003844183	102995333	102995397

Expression profiles

Bgee: expression breadth ubiquitous, 114 present calls, max score 95.83.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0499 / max 47.3639, expressed in 3 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
97775	0.0499	3

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	95.83	gold quality
male germ cell	CL:0000015	94.55	gold quality
left testis	UBERON:0004533	93.08	gold quality
right testis	UBERON:0004534	92.26	gold quality
testis	UBERON:0000473	89.87	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	81.88	gold quality
adult organism	UBERON:0007023	64.61	gold quality
buccal mucosa cell	CL:0002336	59.31	silver quality
decidua	UBERON:0002450	56.55	gold quality
tibialis anterior	UBERON:0001385	55.88	silver quality
cranial nerve II	UBERON:0000941	54.60	gold quality
ileal mucosa	UBERON:0000331	54.07	gold quality
pancreatic ductal cell	CL:0002079	53.84	silver quality
hair follicle	UBERON:0002073	52.80	gold quality
deltoid	UBERON:0001476	50.61	silver quality
quadriceps femoris	UBERON:0001377	50.47	gold quality
frontal pole	UBERON:0002795	50.41	gold quality
middle frontal gyrus	UBERON:0002702	50.30	gold quality
paraflocculus	UBERON:0005351	50.18	gold quality
Brodmann (1909) area 10	UBERON:0013541	50.18	gold quality
thymus	UBERON:0002370	50.17	gold quality
epithelial cell of pancreas	CL:0000083	50.13	gold quality
vastus lateralis	UBERON:0001379	49.45	gold quality
Brodmann (1909) area 46	UBERON:0006483	49.30	gold quality
blood vessel layer	UBERON:0004797	49.29	gold quality
cerebellar vermis	UBERON:0004720	49.25	gold quality
cervix squamous epithelium	UBERON:0006922	49.20	gold quality
olfactory bulb	UBERON:0002264	48.92	gold quality
choroid plexus epithelium	UBERON:0003911	48.89	gold quality
myocardium	UBERON:0002349	48.87	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.43
E-ENAD-17	no	15.84

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

38 targeting CYLC2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-518D-5P	100.00	67.51	979
HSA-MIR-518E-5P	100.00	67.66	954
HSA-MIR-518F-5P	100.00	67.51	979
HSA-MIR-519A-5P	100.00	67.66	954
HSA-MIR-519B-5P	100.00	67.66	954
HSA-MIR-519C-5P	100.00	67.66	954
HSA-MIR-520C-5P	100.00	67.51	979
HSA-MIR-522-5P	100.00	67.66	954
HSA-MIR-523-5P	100.00	67.66	954
HSA-MIR-526A-5P	100.00	67.51	979
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-3912-5P	99.95	66.11	925
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-3140-3P	99.88	68.47	2069
HSA-MIR-944	99.82	70.85	3042
HSA-MIR-205-5P	99.81	70.05	1557
HSA-MIR-4320	99.75	65.80	793
HSA-MIR-4699-3P	99.71	70.15	3142
HSA-MIR-5004-3P	99.54	68.27	1371
HSA-MIR-766-3P	99.47	65.24	1811
HSA-MIR-183-3P	99.41	69.41	1598
HSA-MIR-103A-1-5P	99.39	67.78	1545
HSA-MIR-103A-2-5P	99.39	67.72	1577
HSA-MIR-4427	99.34	70.33	1854
HSA-MIR-485-5P	99.10	64.78	1889
HSA-MIR-6884-5P	99.10	64.50	1987
HSA-MIR-382-3P	98.83	67.10	1074
HSA-MIR-6728-3P	98.63	67.63	1534
HSA-MIR-676-5P	98.49	68.87	1492

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Cylc2	ENSMUSG00000039555
rattus_norvegicus	Cylc2	ENSRNOG00000022406

Paralogs (1): CYLC1 (ENSG00000183035)

Protein

Protein identifiers

Cylicin-2 — Q14093 (reviewed: Q14093)

Alternative names: Cylicin II, Multiple-band polypeptide II

All UniProt accessions (1): Q14093

UniProt curated annotations — full annotation on UniProt →

Function. Plays a role in the establishment of normal sperm morphology during spermatogenesis. It is required for acrosome attachment to the nuclear envelope, and proper manchette elongation and disassembly.

Subcellular location. Cytoplasm. Cytoskeleton. Perinuclear theca. Calyx.

Tissue specificity. Testis.

RefSeq proteins (1): NP_001331* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026189	CYLC	Family
IPR029354	Cylicin_N	Domain

Pfam: PF15241

UniProt features (17 total): sequence variant 5, compositionally biased region 4, region of interest 4, repeat 3, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q14093-F1	50.39	0.00

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 58 (showing top): XU_HGF_TARGETS_REPRESSED_BY_AKT1_DN, GOBP_MALE_GAMETE_GENERATION, MODULE_120, WEBER_METHYLATED_LCP_IN_FIBROBLAST_DN, GOBP_DEVELOPMENTAL_PROCESS_INVOLVED_IN_REPRODUCTION, MODULE_175, GOMF_STRUCTURAL_CONSTITUENT_OF_CYTOSKELETON, GOMF_STRUCTURAL_MOLECULE_ACTIVITY, IWANAGA_CARCINOGENESIS_BY_KRAS_PTEN_UP, NFE2L2.V2, GSE13522_CTRL_VS_T_CRUZI_BRAZIL_STRAIN_INF_SKIN_DN, GOCC_EXTERNAL_ENCAPSULATING_STRUCTURE, MIR6867_5P, GSE10856_CTRL_VS_TNFRSF6B_IN_MACROPHAGE_DN, MIR103A_2_5P

GO Biological Process (3): spermatogenesis (GO:0007283), cell differentiation (GO:0030154), cytoskeleton organization (GO:0007010)

GO Molecular Function (1): structural constituent of cytoskeleton (GO:0005200)

GO Cellular Component (5): nucleus (GO:0005634), cytoskeletal calyx (GO:0033150), cytoplasm (GO:0005737), cytoskeleton (GO:0005856), perinuclear theca (GO:0033011)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoskeleton	2
cellular anatomical structure	2
developmental process involved in reproduction	1
male gamete generation	1
cellular developmental process	1
organelle organization	1
structural molecule activity	1
cytoskeleton organization	1
intracellular membrane-bounded organelle	1
perinuclear theca	1
intracellular anatomical structure	1
intracellular membraneless organelle	1
perinuclear region of cytoplasm	1

Protein interactions and networks

STRING

646 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CYLC2	CCIN	Q13939	962
CYLC2	CATSPERG	Q6ZRH7	565
CYLC2	CSNK2A2IP	A0A1B0GTH6	547
CYLC2	SPATA6	Q9NWH7	514
CYLC2	CBY2	Q8NA61	512
CYLC2	SPATA31E1	Q6ZUB1	507
CYLC2	OR2T10	Q8NGZ9	505
CYLC2	CLXN	Q9HAE3	484
CYLC2	ZCCHC2	Q9C0B9	461
CYLC2	OR52M1	Q8NGK5	434
CYLC2	DHX35	Q9H5Z1	425
CYLC2	ZNF555	Q8NEP9	418
CYLC2	SPMIP9	Q96LM6	396
CYLC2	ARMC3	Q5W041	391
CYLC2	SPATA24	Q86W54	378

IntAct

16 interactions, top by confidence:

A	B	Type	Score
CYLC2	RSL1D1	psi-mi:“MI:0915”(physical association)	0.400
CYLC2	HNRNPM	psi-mi:“MI:0915”(physical association)	0.400
AURKA	CYLC2	psi-mi:“MI:0915”(physical association)	0.370
BUB1	CYLC2	psi-mi:“MI:0915”(physical association)	0.370
CYLC2	CDKN2A	psi-mi:“MI:0915”(physical association)	0.370
EGFR	CYLC2	psi-mi:“MI:0915”(physical association)	0.370
CYLC2	ERBB2	psi-mi:“MI:0915”(physical association)	0.370
MAP2K4	CYLC2	psi-mi:“MI:0915”(physical association)	0.370
MCC	CYLC2	psi-mi:“MI:0915”(physical association)	0.370
MLH1	CYLC2	psi-mi:“MI:0915”(physical association)	0.370
MLH3	CYLC2	psi-mi:“MI:0915”(physical association)	0.370
MUTYH	CYLC2	psi-mi:“MI:0915”(physical association)	0.370
NRAS	CYLC2	psi-mi:“MI:0915”(physical association)	0.370
CYLC2	SMAD2	psi-mi:“MI:0915”(physical association)	0.370
CYLC2	STK11	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (28): CYLC2 (Negative Genetic), CYLC2 (Proximity Label-MS), CYLC2 (Proximity Label-MS), CYLC2 (Two-hybrid), CYLC2 (Two-hybrid), CYLC2 (Two-hybrid), CYLC2 (Two-hybrid), CYLC2 (Two-hybrid), CYLC2 (Two-hybrid), CYLC2 (Two-hybrid), CYLC2 (Two-hybrid), CYLC2 (Two-hybrid), CYLC2 (Two-hybrid), CYLC2 (Two-hybrid), CYLC2 (Two-hybrid)

ESM2 similar proteins: A0A060XQP6, A0A1S4FQ37, A2VD23, A3KQQ9, A7E371, B3A0Q3, B3EWZ0, B3EWZ1, B3EWZ4, B7W112, D1FQ14, E9Q9K5, G5EC21, O01949, O16883, O43493, O46203, O55188, O84462, P08721, P10451, P10923, P13665, P14287, P19814, P23498, P31096, P31097, P31098, P31936, P35662, P35663, P98193, Q13316, Q14093, Q28139, Q5MIT9, Q5SRN2, Q5UQ32, Q62313

Diamond homologs: A0A1B0GR13, A0A571BEE2, P35662, P35663, Q14093, Q28092

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 15 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Cell Cycle	5	13.9×	7e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

80 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	64
Likely benign	12
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

726 predictions. Top by Δscore:

Variant	Effect	Δscore
9:103001573:A:AG	acceptor_gain	1.0000
9:103001576:A:AG	acceptor_gain	1.0000
9:103001577:G:GG	acceptor_gain	1.0000
9:103003140:A:AG	acceptor_gain	1.0000
9:103003141:G:GA	acceptor_gain	1.0000
9:103003141:GTCA:G	acceptor_gain	1.0000
9:103003264:G:GG	donor_gain	1.0000
9:102995393:AGATT:A	donor_gain	0.9900
9:102995394:GATT:G	donor_gain	0.9900
9:102995394:GATTG:G	donor_gain	0.9900
9:102995395:ATT:A	donor_gain	0.9900
9:102995398:G:GG	donor_gain	0.9900
9:103001577:GC:G	acceptor_gain	0.9900
9:103001577:GCC:G	acceptor_gain	0.9900
9:103003141:GT:G	acceptor_gain	0.9900
9:103003141:GTC:G	acceptor_gain	0.9900
9:103003260:TTCTG:T	donor_loss	0.9900
9:103003262:CTG:C	donor_loss	0.9900
9:103003263:TGTAA:T	donor_loss	0.9900
9:103003264:G:GC	donor_loss	0.9900
9:103003265:T:TC	donor_loss	0.9900
9:103003275:A:T	donor_gain	0.9900
9:102995362:C:T	donor_gain	0.9800
9:102995396:TT:T	donor_gain	0.9800
9:102995396:TTG:T	donor_loss	0.9800
9:102995397:TGT:T	donor_loss	0.9800
9:102995398:G:T	donor_loss	0.9800
9:102995399:TAAGT:T	donor_loss	0.9800
9:103001574:A:G	acceptor_gain	0.9800
9:103001615:CCAG:C	donor_loss	0.9800

AlphaMissense

2320 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:103004742:G:C	W76C	0.991
9:103004742:G:T	W76C	0.991
9:103003192:T:C	F37L	0.989
9:103003194:T:A	F37L	0.989
9:103003194:T:G	F37L	0.989
9:103004740:T:A	W76R	0.989
9:103004740:T:C	W76R	0.989
9:103003180:T:C	F33L	0.984
9:103003182:T:A	F33L	0.984
9:103003182:T:G	F33L	0.984
9:103003165:T:A	W28R	0.983
9:103003165:T:C	W28R	0.983
9:103003227:A:C	R48S	0.983
9:103003227:A:T	R48S	0.983
9:103004744:T:C	M77T	0.974
9:103003193:T:C	F37S	0.973
9:103004789:T:C	L92S	0.973
9:103003200:A:C	K39N	0.972
9:103003200:A:T	K39N	0.972
9:103003170:T:A	N29K	0.971
9:103003170:T:G	N29K	0.971
9:103003167:G:C	W28C	0.970
9:103003167:G:T	W28C	0.970
9:103004765:T:C	I84T	0.969
9:103004799:G:C	R95S	0.967
9:103004799:G:T	R95S	0.967
9:103004756:T:C	L81S	0.964
9:103003193:T:G	F37C	0.961
9:103003187:T:C	L35P	0.959
9:103004792:C:A	A93D	0.959

dbSNP variants (sampled 300 via entrez): RS1000073503 (9:103015861 T>A), RS1000152321 (9:102999096 G>A), RS1000182484 (9:103018575 A>G), RS1000206693 (9:102998733 A>G), RS1000286313 (9:103012153 G>A), RS1000555773 (9:103018356 C>T), RS1000617442 (9:103014382 T>A,C), RS1000673998 (9:103014227 TAA>T), RS1000832304 (9:103008597 C>A), RS1000942363 (9:103008668 T>C), RS1001087279 (9:103003761 A>C), RS1001123304 (9:102997185 G>T), RS1001158895 (9:102997884 A>T), RS1001182259 (9:102996407 T>G), RS1001204216 (9:103008287 T>A)

Disease associations

OMIM: gene MIM:604035 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
autism spectrum disorder	Limited	Autosomal dominant

Mondo (2): primary ovarian failure (MONDO:0005387), autism spectrum disorder (MONDO:0005258)

Orphanet (1): NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST001762_829	Obesity-related traits	7.000000e-06
GCST002682_9	Tourette’s syndrome or obsessive-compulsive disorder	5.000000e-06
GCST009391_1177	Metabolite levels	4.000000e-06
GCST010396_101	Gut microbiota (bacterial taxa, hurdle binary method)	4.000000e-07
GCST012015_4	Chronic rhinosinusitis	5.000000e-06

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004338	body weight
EFO:0010454	adenosine monophosphate measurement
EFO:0007874	gut microbiome measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

6 total (human), top 6 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
2-palmitoylglycerol	increases expression	1
Silicon Dioxide	decreases expression	1
Tamoxifen	increases expression	1
Aflatoxin B1	increases methylation	1
Raloxifene Hydrochloride	increases expression	1
Magnetite Nanoparticles	decreases expression	1

Clinical trials (associated diseases)

375 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT01302964	PHASE3	COMPLETED	Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
NCT01706523	PHASE3	TERMINATED	Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
NCT01825798	PHASE3	COMPLETED	Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
NCT01972074	PHASE3	COMPLETED	Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder
NCT02985749	PHASE3	COMPLETED	A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder
NCT03197922	PHASE3	COMPLETED	Treatment of Encopresis in Children With Autism Spectrum Disorders
NCT03504917	PHASE3	TERMINATED	A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
NCT03553875	PHASE3	TERMINATED	Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
NCT03640156	PHASE3	COMPLETED	Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin
NCT03715153	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
NCT03715166	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
NCT04233502	PHASE3	WITHDRAWN	Efficacy and Safety of Slenyto for Insomnia in Children With ASD
NCT04578756	PHASE3	COMPLETED	Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder